Herantis Pharma to participate in Redeye Hosted Events: Investor Lunch and Redeye Growth Day
Herantis Pharma Plc, Press Release, 23 May 2023 at 10:00 A.M. EEST Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that Redeye will be hosting events for investors with Herantis Pharma, CEO Antti Vuolanto, and CFO Tone Kvåle. Lunch meeting: Following the recent announcement of the first-in-human clinical study start, Herantis will give a company update, followed by discussion/Q&A. As an introduction, Redeye analyst Fredrik Thor will give a brief case summary and his view of the